Monday, June 2, 2025
Social icon element need JNews Essential plugin to be activated.
No Result
View All Result
Stocks and Markets Update
  • Home
  • Business
  • Economy
  • Stocks
  • Investing
  • Markets
  • Crypto
  • Real Estate
  • PF
  • Forex
  • Startups
  • Fintech
  • Analysis
  • Home
  • Business
  • Economy
  • Stocks
  • Investing
  • Markets
  • Crypto
  • Real Estate
  • PF
  • Forex
  • Startups
  • Fintech
  • Analysis
No Result
View All Result
Stocks and Markets Update
No Result
View All Result

Novo Nordisk sees double-digit FY growth as Q4 profit beats estimate By Reuters

January 31, 2024
in Business
Reading Time: 2 mins read
A A
0
Novo Nordisk sees double-digit FY growth as Q4 profit beats estimate By Reuters

[ad_1]

Novo Nordisk sees double-digit FY growth as Q4 profit beats estimate
© Reuters. The brand of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little

COPENHAGEN/LONDON (Reuters) -Novo Nordisk on Wednesday reported fourth-quarter working revenue above expectations and in addition forecast one other yr of double-digit document gross sales and working revenue development because of its well-liked weight-loss drug Wegovy.

“We’re very happy with the sturdy efficiency in 2023 reflecting that greater than 40 million folks are actually benefiting from our progressive diabetes and weight problems therapies,” CEO Lars Fruergaard Jorgensen mentioned in an announcement.

The Danish firm mentioned it expects gross sales development this yr between 16% and 25% and working revenue to rise 19%-28% as demand soars for Wegovy and diabetes drug Ozempic, which accommodates the identical lively ingredient.

Analysts on common anticipate Novo Nordisk (NYSE:) to ship gross sales development of 21% this yr, in accordance with LSEG knowledge.

Novo Nordisk, which has raced to extend output amid shortages of Wegovy, mentioned it began steadily rising the provision of the decrease dose power of the drug in america in January.

The corporate has since final Could restricted provide of decrease dose power.

The outcomes underscore Wegovy’s success and Novo’s lead within the fast-growing weight problems drug market, whilst the corporate faces early competitors from U.S. rival Eli Lilly (NYSE:).

Robust demand for Wegovy and Ozempic have propelled Novo’s shares to document highs, making it Europe’s most useful listed firm price greater than 450 billion euros ($487 billion), forward of LVMH.

It additionally supplied an financial bonanza for its residence nation of Denmark.

[ad_2]

Source link

Tags: beatsdoubledigitestimategrowthNordiskNovoprofitReuterssees
Previous Post

Fintech on the Rise in Uzbekistan: A Short Overview – Fintech Schweiz Digital Finance News

Next Post

From Homeless at 17 to Solving the Affordable Housing Crisis

Next Post
From Homeless at 17 to Solving the Affordable Housing Crisis

From Homeless at 17 to Solving the Affordable Housing Crisis

How Do Modern Washing Machines Work

How Do Modern Washing Machines Work

Asia-Pacific stocks mixed after downbeat China PMI data, growing caution ahead of FOMC lat

Asia-Pacific stocks mixed after downbeat China PMI data, growing caution ahead of FOMC lat

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Fintech
  • Forex
  • Investing
  • jutawantoto
  • lingtogel77
  • Market Analysis
  • Markets
  • Personal Finance
  • Real Estate
  • Startups
  • Stock Market
No Result
View All Result

LATEST UPDATES

  • Jutawantoto: 4D Online Toto Togel Site & Prestigious Official Bookie
  • Jutawantoto Login: Trusted Toto Slot 4D Site Bet 100 Silver Best 2025
  • Jutawantoto: The Most Trusted & Best Toto 4D Site in 2025
  • Lingtogel77: Rekomendasi Resmi Platform Situs Toto Slot Terpercaya
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2023 Money Wise Inc.
Money Wise Inc is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Business
  • Economy
  • Stocks
  • Investing
  • Markets
  • Crypto
  • Real Estate
  • PF
  • Forex
  • Startups
  • Fintech
  • Analysis

Copyright © 2023 Money Wise Inc.
Money Wise Inc is not responsible for the content of external sites.